Literature DB >> 18780476

The potential of soluble epoxide hydrolase inhibition in the treatment of cardiac hypertrophy.

Todd R Harris1, Ning Li, Nipanvan Chiamvimonvat, Bruce D Hammock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18780476      PMCID： PMC3748820          DOI： 10.1111/j.1751-7133.2008.08430.x

Source DB:  PubMed          Journal:  Congest Heart Fail        ISSN： 1527-5299


× No keyword cloud information.
  29 in total

Review 1.  NF-kappaB at the crossroads of life and death.

Authors:  Michael Karin; Anning Lin
Journal:  Nat Immunol       Date:  2002-03       Impact factor: 25.606

2.  Is nuclear factor kappaB an attractive therapeutic target for treating cardiac hypertrophy?

Authors:  Nicole H Purcell; Jeffery D Molkentin
Journal:  Circulation       Date:  2003-08-12       Impact factor: 29.690

Review 3.  Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.

Authors:  Thomas Force; Keisuke Kuida; Mark Namchuk; Keykavous Parang; John M Kyriakis
Journal:  Circulation       Date:  2004-03-16       Impact factor: 29.690

Review 4.  Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death.

Authors:  Orlando F Bueno; Jeffery D Molkentin
Journal:  Circ Res       Date:  2002-11-01       Impact factor: 17.367

5.  Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy.

Authors:  Shinichi Hirotani; Kinya Otsu; Kazuhiko Nishida; Yoshiharu Higuchi; Takashi Morita; Hiroyuki Nakayama; Osamu Yamaguchi; Toshiaki Mano; Yasushi Matsumura; Hikaru Ueno; Michihiko Tada; Masatsugu Hori
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

6.  Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

Authors:  Giovanni Esposito; Antonio Rapacciuolo; Sathyamangla V Naga Prasad; Hideyuki Takaoka; Steven A Thomas; Walter J Koch; Howard A Rockman
Journal:  Circulation       Date:  2002-01-01       Impact factor: 29.690

Review 7.  The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states.

Authors:  Ursula C Brewster; John F Setaro; Mark A Perazella
Journal:  Am J Med Sci       Date:  2003-07       Impact factor: 2.378

Review 8.  Hypertrophy of the heart: a new therapeutic target?

Authors:  Norbert Frey; Hugo A Katus; Eric N Olson; Joseph A Hill
Journal:  Circulation       Date:  2004-04-06       Impact factor: 29.690

9.  Arachidonic and eicosapentaenoic acid metabolism by human CYP1A1: highly stereoselective formation of 17(R),18(S)-epoxyeicosatetraenoic acid.

Authors:  Dieter Schwarz; Pyotr Kisselev; Spencer S Ericksen; Grazyna D Szklarz; Alexey Chernogolov; Horst Honeck; Wolf-Hagen Schunck; Ivar Roots
Journal:  Biochem Pharmacol       Date:  2004-04-15       Impact factor: 5.858

10.  Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy.

Authors:  Sudhiranjan Gupta; Nicole H Purcell; Anning Lin; Subha Sen
Journal:  J Cell Biol       Date:  2002-12-16       Impact factor: 10.539
View more
  16 in total

1.  Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.

Authors:  Hsing-Ju Tsai; Sung Hee Hwang; Christophe Morisseau; Jun Yang; Paul D Jones; Takeo Kasagami; In-Hae Kim; Bruce D Hammock
Journal:  Eur J Pharm Sci       Date:  2010-03-30       Impact factor: 4.384

Review 2.  Humble beginnings with big goals: Small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders.

Authors:  Sydney Zarriello; Julian P Tuazon; Sydney Corey; Samantha Schimmel; Mira Rajani; Anna Gorsky; Diego Incontri; Bruce D Hammock; Cesar V Borlongan
Journal:  Prog Neurobiol       Date:  2018-11-14       Impact factor: 11.685

Review 3.  Soluble epoxide hydrolase inhibitors and heart failure.

Authors:  Hong Qiu; Ning Li; Jun-Yan Liu; Todd R Harris; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Cardiovasc Ther       Date:  2011-04       Impact factor: 3.023

Review 4.  Recent updates on novel therapeutic targets of cardiovascular diseases.

Authors:  Muhammad Afzal
Journal:  Mol Cell Biochem       Date:  2020-08-26       Impact factor: 3.396

5.  1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Authors:  Tristan E Rose; Christophe Morisseau; Jun-Yan Liu; Bora Inceoglu; Paul D Jones; James R Sanborn; Bruce D Hammock
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

6.  Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability.

Authors:  Stevan Pecic; Amir A Zeki; Xiaoming Xu; Gina Y Jin; Shuwei Zhang; Sean Kodani; Marlin Halim; Christophe Morisseau; Bruce D Hammock; Shi-Xian Deng
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-03-20       Impact factor: 3.072

7.  Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury.

Authors:  Ahmed Bettaieb; Shinichiro Koike; Samah Chahed; Yi Zhao; Santana Bachaalany; Nader Hashoush; James Graham; Huma Fatima; Peter J Havel; Artiom Gruzdev; Darryl C Zeldin; Bruce D Hammock; Fawaz G Haj
Journal:  FEBS J       Date:  2017-05-29       Impact factor: 5.542

8.  Novel drugs targeting hypertension revisited.

Authors:  George W Booz
Journal:  J Cardiovasc Pharmacol       Date:  2010-09       Impact factor: 3.105

9.  Unique mechanistic insights into the beneficial effects of soluble epoxide hydrolase inhibitors in the prevention of cardiac fibrosis.

Authors:  Padmini Sirish; Ning Li; Jun-Yan Liu; Kin Sing Stephen Lee; Sung Hee Hwang; Hong Qiu; Cuifen Zhao; Siu Mei Ma; Javier E López; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-14       Impact factor: 11.205

10.  Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.

Authors:  Ketul R Chaudhary; Mohamed Abukhashim; Sung Hee Hwang; Bruce D Hammock; John M Seubert
Journal:  J Cardiovasc Pharmacol       Date:  2010-01       Impact factor: 3.105
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.